1,2 The findings of these studies suggest that administration of the long-acting analog insulin glargine increases the risk of cancer in patients with diabetes mellitus, whereas the biguanide ...

Lilly and Boehringer Ingelheim have gained EU approval for their biosimilar version of Sanofi's blockbuster insulin product Lantus (insulin glargine). The Europe-wide approval is the first ever ...

New insulin analogues such as the long-acting analogue insulin glargine may represent beneficial treatment options in pregnancy by ensuring that patients achieve excellent glycemic control without ...

Insulin Biosimilar MarketThe global insulin biosimilar market is on track for significant expansion, with an estimated valuation of approximately USD 3,008.0 million in 2024. Exhibiting a year-on-year ...

Although HbA1c testing remains the gold standard for glucose monitoring in type 1 and type 2 diabetes, limitations include ...

Renee Rucinsky, DVM, DABVP, discussed insulin therapy and SGLT2 inhibitors in her lecture at the Fetch dvm360 conference in Atlantic City ...

A recent study conducted by researchers from The GRADE Study Research Group looked at how well different medications work ...

Objective — To determine the pharmacokinetic and pharmacodynamic dose-response effects of insulin glargine administered subcutaneously in individuals with type 2 diabetes. Research design and ...

The phase 3 SURPASS-4 trial published in 2021 established that tirzepatide lowers blood sugar and supports weight loss better than insulin glargine (a long-acting insulin) for type 2 diabetes (T2D).

Adalimumab biosimilar market shares have steadily increased, but challenges remain due to pricing strategies and limited government support, according to the Samsung Bioepis report.

whereas the most-covered drug (Lantus (insulin glargine)) was present in nearly every (97.8%) plan. We also examined whether coverage varied by drug characteristics (data not shown but available ...

A settlement by Wyoming Attorney General Bridget Hill guarantees that residents who are not enrolled in government health ...